Evicenter
MarkdownMedical informationP&T meetings
Aqneursa (levacetylleucine)

Ataxia-telangiectasia

Also known as IB1001
Manufacturer
IntraBio
Last updated
209 sources

Section 4 of 6

Clinical evidence

259 evidence topics · 42 sources

Study summaries

IB1001-303

Objective
Location and study date
Study dates in the registry record
FieldRegistry value
Study start (actual)“2025-03-18”
Primary completion (estimated)“2027-12-31”
Study completion (estimated)“2028-06-01”
First posted“2024-11-04”
Last update posted“2025-07-03”
European Union trial start and recruitment start by member state
Member stateDecision dateTrial start dateRecruitment start date
Germany“25/03/2025”“13/05/2025”“13/05/2025”
Spain“25/03/2025”“13/05/2025”“29/05/2025”
Slovakia“26/03/2025”“13/05/2025”“19/05/2025”
Study design
Eligibility criteria
Exclusion criteria

“Simultaneous participation in another clinical study or participation in any clinical study involving administration of an investigational medicinal product (IMP; 'study drug') for at least 42 days prior to Visit 1.” (opens the source at this quote in a new tab)

“Patients with a physical or psychiatric condition which, at the investigator's discretion and in consultation with the Medical Monitor and Sponsor (as applicable), may put the patient at risk, may confound the study results, or may interfere with the patient's participation in the clinical study, i.e. reliably perform study assessments.” (opens the source at this quote in a new tab)

“Known or persistent use, misuse, or dependency of medication, drugs, or alcohol.” (opens the source at this quote in a new tab)

“Current or planned pregnancy or women who are breastfeeding.” (opens the source at this quote in a new tab)

“Patients with severe vision or hearing impairment (that is not corrected by glasses or hearing aids) that, at the investigator's discretion, interferes with their ability to perform study assessments.” (opens the source at this quote in a new tab)

“Patients who have been diagnosed with arthritis or other musculoskeletal disorders affecting joints, muscles, ligaments, and/or nerves that by themselves affects patient's mobility and, at the investigator's discretion, interferes with their ability to perform study assessments.” (opens the source at this quote in a new tab)

Treatment
Study outcomes
Rationale for using the scale for the assessment and rating of ataxia as the primary endpoint
Functional SARA: FDA rationale for domain selection and rescoring in the Niemann-Pick disease type C review

“The Agency recommended an fSARA which focuses on four domains: gait, stance, sitting, and speech disturbance. For these four domains, the Agency recommended a modification to the scoring so that each domain has five possible scores: 0 (normal), 1, 2, 3, and 4 (worst severity); thus, the total fSARA score ranges from 0 to 16.” (opens the source at this quote in a new tab)

“Consistent with Agency’s approach in other rare progressive neurodegenerative indications (Potashman et al. 2024b), several domains of the SARA (finger chase, nose to finger, fast alternating hand movements, heel to shin slide) assess neurologic exam findings.” (opens the source at this quote in a new tab)

“These neurologic exam findings do not directly assess the patient’s ability to function, nor do they reflect clinically meaningful change in a patient’s ability to perform daily functions, making them unsuitable for inclusion in a primary efficacy endpoint to convey clinical benefit.” (opens the source at this quote in a new tab)

“Scoring of the SARA domains varies (e.g., gait comprises 9 levels, speech comprises 7 levels), which interferes with the interpretation of the total score.” (opens the source at this quote in a new tab)

“As the Applicant did not revise the response categories of the SARA domains, the Agency rescored to create the same number of response categories across each domain (Table 23) to ensure equal representation of each domain in the total score and interpretability of a 1-point change as clinically meaningful (Potashman et al. 2024a).” (opens the source at this quote in a new tab)

Functional SARA: FDA-recommended rescoring of the four SARA domains
SARA domainOriginal item scoreModified domain score
Gait“0 = Normal, no difficulties in walking, turning and walking tandem (up to one misstep allowed)”“0”
Gait“1 = Slight difficulties, only visible when walking 10 consecutive steps in tandem”“1”
Gait“2 = Clearly abnormal, tandem walking >10 steps not possible”“1”
Gait“3 = Considerable staggering, difficulties in half-turn, but without support”“2”
Gait“4 = Marked staggering, intermittent support of the wall required”“2”
Gait“5 = Severe staggering, permanent support of one stick or light support by one arm required”“2”
Gait“6 = Walking >10 m only with strong support (two special sticks or stroller or accompanying person)”“3”
Gait“7 = Walking <10 m only with strong support (two special sticks or stroller or accompanying person)”“3”
Gait“8 = Unable to walk, even supported”“4”
Stance“0 = Normal, able to stand in tandem for >10 s”“0”
Stance“1 = Able to stand with feet together without sway, but not in tandem for >10s”“1”
Stance“2 = Able to stand with feet together for >10 s, but only with sway”“1”
Stance“3 = Able to stand for >10 s without support in natural position, but not with feet together”“2”
Stance“4 = Able to stand for >10 s in natural position only with intermittent support”“3”
Stance“5 = Able to stand >10 s in natural position only with constant support of one arm”“3”
Stance“6 = Unable to stand for >10 s even with constant support of one arm”“4”
Sitting“0 = Normal, no difficulties sitting >10 sec”“0”
Sitting“1 = Slight difficulties, intermittent sway”“1”
Sitting“2 = Constant sway, but able to sit >10 s without support”“2”
Sitting“3 = Able to sit for >10 s only with intermittent support”“3”
Sitting“4 = Unable to sit for >10 s without continuous support”“4”
Speech disturbance“0 = Normal”“0”
Speech disturbance“1 = Suggestion of speech disturbance”“1”
Speech disturbance“2 = Impaired speech, but easy to understand”“1”
Speech disturbance“3 = Occasional words difficult to understand”“2”
Speech disturbance“4 = Many words difficult to understand”“3”
Speech disturbance“5 = Only single words understandable”“4”
Speech disturbance“6 = Speech unintelligible / anarthria”“4”
International Cooperative Ataxia Rating Scale
Quality-of-life instruments and exit interviews
Statistical analysis description
Number of participants (Planned and analyzed)
Estimated enrollment in the registry record
FieldRegistry value
Enrollment (estimated)“60”
Participants screened, randomized, and analyzed
PopulationParticipants
Screened“77”View highlighted excerpt for this quote
Excluded for not meeting inclusion criteria“Four”View highlighted excerpt for this quote
Enrolled and randomly assigned“73”View highlighted excerpt for this quote
Assigned to levacetylleucine followed by placebo“36”View highlighted excerpt for this quote
Assigned to placebo followed by levacetylleucine“37”View highlighted excerpt for this quote
Included in the primary analysis and safety sets“73”View highlighted excerpt for this quote
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Demographics and baseline characteristics by treatment sequence
CharacteristicTotal, n = 73Levacetylleucine to placebo, n = 36Placebo to levacetylleucine, n = 37
Pediatric, younger than 18 years“47 (64%)”View highlighted excerpt for this quote“23 (64%)”View highlighted excerpt for this quote“24 (65%)”View highlighted excerpt for this quote
Adult, 18 years or older“26 (36%)”View highlighted excerpt for this quote“13 (36%)”View highlighted excerpt for this quote“13 (35%)”View highlighted excerpt for this quote
Female“38 (52%)”View highlighted excerpt for this quote“17 (47%)”View highlighted excerpt for this quote“21 (57%)”View highlighted excerpt for this quote
Male“35 (48%)”View highlighted excerpt for this quote“19 (53%)”View highlighted excerpt for this quote“16 (43%)”View highlighted excerpt for this quote
Hispanic or Latino“4 (5%)”View highlighted excerpt for this quote“2 (6%)”View highlighted excerpt for this quote“2 (5%)”View highlighted excerpt for this quote
Not Hispanic or Latino“51 (70%)”View highlighted excerpt for this quote“26 (72%)”View highlighted excerpt for this quote“25 (68%)”View highlighted excerpt for this quote
Ethnicity not reported“3 (4%)”View highlighted excerpt for this quote“2 (6%)”View highlighted excerpt for this quote“1 (3%)”View highlighted excerpt for this quote
Ethnicity unknown“15 (21%)”View highlighted excerpt for this quote“6 (17%)”View highlighted excerpt for this quote“9 (24%)”View highlighted excerpt for this quote
Asian“4 (5%)”View highlighted excerpt for this quote“2 (6%)”View highlighted excerpt for this quote“2 (5%)”View highlighted excerpt for this quote
Black or African American“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
Native Hawaiian or other Pacific Islander“1 (1%)”View highlighted excerpt for this quote“1 (3%)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
White“55 (75%)”View highlighted excerpt for this quote“28 (78%)”View highlighted excerpt for this quote“27 (73%)”View highlighted excerpt for this quote
Race not reported“9 (12%)”View highlighted excerpt for this quote“3 (8%)”View highlighted excerpt for this quote“6 (16%)”View highlighted excerpt for this quote
Other race“4 (5%)”View highlighted excerpt for this quote“2 (6%)”View highlighted excerpt for this quote“2 (5%)”View highlighted excerpt for this quote
Age at diagnosis: early-infantile, younger than 2 years“51 (70%)”View highlighted excerpt for this quote“24 (67%)”View highlighted excerpt for this quote“27 (73%)”View highlighted excerpt for this quote
Age at diagnosis: late-infantile, 2 to younger than 6 years“16 (22%)”View highlighted excerpt for this quote“8 (22%)”View highlighted excerpt for this quote“8 (22%)”View highlighted excerpt for this quote
Age at diagnosis: juvenile, 6 to younger than 15 years“3 (4%)”View highlighted excerpt for this quote“2 (6%)”View highlighted excerpt for this quote“1 (3%)”View highlighted excerpt for this quote
Age at diagnosis: adolescent or adult, 15 years or older“3 (4%)”View highlighted excerpt for this quote“2 (6%)”View highlighted excerpt for this quote“1 (3%)”View highlighted excerpt for this quote
Weight 15 to less than 25 kg, 2 g per day“18 (25%)”View highlighted excerpt for this quote“8 (22%)”View highlighted excerpt for this quote“10 (27%)”View highlighted excerpt for this quote
Weight 25 to less than 35 kg, 3 g per day“17 (23%)”View highlighted excerpt for this quote“9 (25%)”View highlighted excerpt for this quote“8 (22%)”View highlighted excerpt for this quote
Weight 35 kg or more, 4 g per day“38 (52%)”View highlighted excerpt for this quote“19 (53%)”View highlighted excerpt for this quote“19 (51%)”View highlighted excerpt for this quote
Efficacy results
fSARA total score by period and treatment sequence, prescribing information
VariableTreatment Sequence 1: AQNEURSA then placeboTreatment Sequence 2: placebo then AQNEURSA
Baseline, participants“N=36”“N=37”
Baseline, mean (SD)“7.3 (2.6)”“8.5 (2.5)”
Period I, participants“N=34”“N=37”
Period I, mean (SD)“6.6 (2.8)”“8.5 (2.6)”
Period II, participants“N=35”“N=35”
Period II, mean (SD)“7.0 (3.1)”“7.8 (2.7)”
Least squares mean fSARA score by treatment, prescribing information
TreatmentLeast squares mean fSARA score (SE)
AQNEURSA“7.2 (0.1)”
Placebo“7.8 (0.1)”
Treatment difference (95% CI)“-0.6 (-0.9, -0.2)”
Primary and secondary efficacy endpoints at end of treatment, peer-reviewed publication
EndpointEnd of treatment, levacetylleucine, mean (SD); nEnd of treatment, placebo, mean (SD); nMean change from baseline, levacetylleucine (SD)Mean change from baseline, placebo (SD)Linear mixed model treatment effect (95% CI)
SARA (primary)“17·96 (7·30); n=69”View highlighted excerpt for this quote“19·73 (7·39); n=72”View highlighted excerpt for this quote“−1·92 (2·81)”View highlighted excerpt for this quote“−0·14 (2·38)”View highlighted excerpt for this quote“−1·88 (−2·70 to −1·06)”View highlighted excerpt for this quote
FDA functional SARA“7·20 (2·83); n=69”View highlighted excerpt for this quote“7·76 (2·96); n=72”View highlighted excerpt for this quote“−0·65 (1·16)”View highlighted excerpt for this quote“−0·10 (1·02)”View highlighted excerpt for this quote“−0·57 (−0·92 to −0·23)”View highlighted excerpt for this quote
SCAFI“−0·41 (1·06); n=70”View highlighted excerpt for this quote“−0·45 (1·05); n=72”View highlighted excerpt for this quote“0·06 (0·28)”View highlighted excerpt for this quote“0·04 (0·24)”View highlighted excerpt for this quote“0·01 (−0·06 to 0·07)”View highlighted excerpt for this quote
ICARS“47·30 (18·67); n=69”View highlighted excerpt for this quote“49·85 (19·10); n=72”View highlighted excerpt for this quote“−4·22 (7·77)”View highlighted excerpt for this quote“−1·69 (6·09)”View highlighted excerpt for this quote“−2·84 (−4·87 to −0·81)”View highlighted excerpt for this quote
Investigator's Clinical Global Impression of Improvement“3·4 (0·8); n=35”View highlighted excerpt for this quote“3·8 (0·6); n=37”View highlighted excerpt for this quote“−0·6 (0·8)”View highlighted excerpt for this quote“−0·2 (0·6)”View highlighted excerpt for this quote“−0·4 (−0·7 to −0·02)”View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes
Patient-reported, caregiver-reported, and quality-of-life endpoints at end of treatment
EndpointEnd of treatment, levacetylleucine, mean (SD); nEnd of treatment, placebo, mean (SD); nMean change from baseline, levacetylleucine (SD)Mean change from baseline, placebo (SD)
Caregiver Clinical Global Impression of Improvement“3·8 (0·8); n=30”View highlighted excerpt for this quote“3·8 (0·8); n=36”View highlighted excerpt for this quote“−0·2 (0·8)”View highlighted excerpt for this quote“−0·2 (0·8)”View highlighted excerpt for this quote
Patient Clinical Global Impression of Improvement“3·5 (1·0); n=31”View highlighted excerpt for this quote“3·6 (0·9); n=33”View highlighted excerpt for this quote“−0·5 (1·0)”View highlighted excerpt for this quote“−0·4 (0·9)”View highlighted excerpt for this quote
EQ-Visual Analogue Scale“75·8 (20·5); n=70”View highlighted excerpt for this quote“74·0 (22·5); n=71”View highlighted excerpt for this quote“1·3 (15·5)”View highlighted excerpt for this quote“−0·3 (19·2)”View highlighted excerpt for this quote
Pediatric NeuroQuality of Life Upper Extremity Function“52·6 (27·2); n=25”View highlighted excerpt for this quote“54·9 (25·3); n=25”View highlighted excerpt for this quote“−4·9 (11·9)”View highlighted excerpt for this quote“−6·2 (14·6)”View highlighted excerpt for this quote
Adult NeuroQuality of Life Upper Extremity Function“57·4 (18·2); n=15”View highlighted excerpt for this quote“57·2 (19·5); n=15”View highlighted excerpt for this quote“−0·4 (10·8)”View highlighted excerpt for this quote“−0·9 (9·4)”View highlighted excerpt for this quote
Safety results
Prescribing information: adverse reactions in Treatment Period I of Trial 2 at an incidence of 5% or more
Adverse reactionAQNEURSA, N = 36, n (%)Placebo, N = 37, n (%)
Fall“2 (6)”“1 (3)”
Skin laceration“2 (6)”“0 (0)”
Urinary tract infection“2 (6)”“1(3)”
Treatment-emergent adverse events by system organ class
System organ classLevacetylleucine, n = 73, n (%)Levacetylleucine, eventsPlacebo, n = 72, n (%)Placebo, eventsTotal, n = 73, n (%)Total, events
Any treatment emergent adverse event“29 (40%)”View highlighted excerpt for this quote“54”View highlighted excerpt for this quote“25 (35%)”View highlighted excerpt for this quote“75”View highlighted excerpt for this quote“37 (51%)”View highlighted excerpt for this quote“129”View highlighted excerpt for this quote
Infections and infestations“15 (21%)”View highlighted excerpt for this quote“17”View highlighted excerpt for this quote“13 (18%)”View highlighted excerpt for this quote“15”View highlighted excerpt for this quote“22 (30%)”View highlighted excerpt for this quote“32”View highlighted excerpt for this quote
Gastrointestinal disorders“5 (7%)”View highlighted excerpt for this quote“6”View highlighted excerpt for this quote“10 (14%)”View highlighted excerpt for this quote“21”View highlighted excerpt for this quote“12 (16%)”View highlighted excerpt for this quote“27”View highlighted excerpt for this quote
Injury, poisoning, and procedural complications“7 (10%)”View highlighted excerpt for this quote“9”View highlighted excerpt for this quote“5 (7%)”View highlighted excerpt for this quote“7”View highlighted excerpt for this quote“10 (14%)”View highlighted excerpt for this quote“16”View highlighted excerpt for this quote
Respiratory, thoracic, and mediastinal disorders“6 (8%)”View highlighted excerpt for this quote“7”View highlighted excerpt for this quote“5 (7%)”View highlighted excerpt for this quote“8”View highlighted excerpt for this quote“8 (11%)”View highlighted excerpt for this quote“15”View highlighted excerpt for this quote
General disorders and administration site conditions“3 (4%)”View highlighted excerpt for this quote“4”View highlighted excerpt for this quote“3 (4%)”View highlighted excerpt for this quote“3”View highlighted excerpt for this quote“5 (7%)”View highlighted excerpt for this quote“7”View highlighted excerpt for this quote
Nervous system disorders“2 (3%)”View highlighted excerpt for this quote“2”View highlighted excerpt for this quote“3 (4%)”View highlighted excerpt for this quote“4”View highlighted excerpt for this quote“5 (7%)”View highlighted excerpt for this quote“6”View highlighted excerpt for this quote
Skin and subcutaneous tissue disorders“3 (4%)”View highlighted excerpt for this quote“3”View highlighted excerpt for this quote“2 (3%)”View highlighted excerpt for this quote“3”View highlighted excerpt for this quote“5 (7%)”View highlighted excerpt for this quote“6”View highlighted excerpt for this quote
Psychiatric disorders“1 (1%)”View highlighted excerpt for this quote“1”View highlighted excerpt for this quote“2 (3%)”View highlighted excerpt for this quote“3”View highlighted excerpt for this quote“3 (4%)”View highlighted excerpt for this quote“4”View highlighted excerpt for this quote
Renal and urinary disorders“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“3 (4%)”View highlighted excerpt for this quote“3”View highlighted excerpt for this quote“3 (4%)”View highlighted excerpt for this quote“3”View highlighted excerpt for this quote
Eye disorders“2 (3%)”View highlighted excerpt for this quote“2”View highlighted excerpt for this quote“1 (1%)”View highlighted excerpt for this quote“1”View highlighted excerpt for this quote“2 (3%)”View highlighted excerpt for this quote“3”View highlighted excerpt for this quote
Blood and lymphatic system disorders“1 (1%)”View highlighted excerpt for this quote“1”View highlighted excerpt for this quote“1 (1%)”View highlighted excerpt for this quote“1”View highlighted excerpt for this quote“2 (3%)”View highlighted excerpt for this quote“2”View highlighted excerpt for this quote
Investigations“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“2 (3%)”View highlighted excerpt for this quote“2”View highlighted excerpt for this quote“2 (3%)”View highlighted excerpt for this quote“2”View highlighted excerpt for this quote
Metabolism and nutrition disorders“1 (1%)”View highlighted excerpt for this quote“1”View highlighted excerpt for this quote“1 (1%)”View highlighted excerpt for this quote“1”View highlighted excerpt for this quote“2 (3%)”View highlighted excerpt for this quote“2”View highlighted excerpt for this quote
Musculoskeletal and connective tissue disorders“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“2 (3%)”View highlighted excerpt for this quote“2”View highlighted excerpt for this quote“2 (3%)”View highlighted excerpt for this quote“2”View highlighted excerpt for this quote
Hepatobiliary disorders“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (1%)”View highlighted excerpt for this quote“1”View highlighted excerpt for this quote“1 (1%)”View highlighted excerpt for this quote“1”View highlighted excerpt for this quote
Neoplasms benign, malignant and unspecified (including cysts and polyps)“1 (1%)”View highlighted excerpt for this quote“1”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (1%)”View highlighted excerpt for this quote“1”View highlighted excerpt for this quote
Treatment-emergent adverse events reported in two or more participants during either treatment
Preferred termLevacetylleucine, n = 73, n (%)Levacetylleucine, eventsPlacebo, n = 72, n (%)Placebo, eventsTotal, n = 73, n (%)Total, events
Cough“6 (8%)”View highlighted excerpt for this quote“7”View highlighted excerpt for this quote“2 (3%)”View highlighted excerpt for this quote“3”View highlighted excerpt for this quote“6 (8%)”View highlighted excerpt for this quote“10”View highlighted excerpt for this quote
Upper respiratory tract infection“3 (4%)”View highlighted excerpt for this quote“3”View highlighted excerpt for this quote“3 (4%)”View highlighted excerpt for this quote“3”View highlighted excerpt for this quote“6 (8%)”View highlighted excerpt for this quote“6”View highlighted excerpt for this quote
Fall“3 (4%)”View highlighted excerpt for this quote“3”View highlighted excerpt for this quote“2 (3%)”View highlighted excerpt for this quote“2”View highlighted excerpt for this quote“5 (7%)”View highlighted excerpt for this quote“5”View highlighted excerpt for this quote
Pyrexia“3 (4%)”View highlighted excerpt for this quote“4”View highlighted excerpt for this quote“2 (3%)”View highlighted excerpt for this quote“2”View highlighted excerpt for this quote“5 (7%)”View highlighted excerpt for this quote“6”View highlighted excerpt for this quote
Diarrhoea“2 (3%)”View highlighted excerpt for this quote“2”View highlighted excerpt for this quote“4 (6%)”View highlighted excerpt for this quote“4”View highlighted excerpt for this quote“5 (7%)”View highlighted excerpt for this quote“6”View highlighted excerpt for this quote
Vomiting“1 (1%)”View highlighted excerpt for this quote“1”View highlighted excerpt for this quote“4 (6%)”View highlighted excerpt for this quote“7”View highlighted excerpt for this quote“5 (7%)”View highlighted excerpt for this quote“8”View highlighted excerpt for this quote
Urinary tract infection“2 (3%)”View highlighted excerpt for this quote“2”View highlighted excerpt for this quote“2 (3%)”View highlighted excerpt for this quote“2”View highlighted excerpt for this quote“3 (4%)”View highlighted excerpt for this quote“4”View highlighted excerpt for this quote
Abdominal pain“1 (1%)”View highlighted excerpt for this quote“1”View highlighted excerpt for this quote“3 (4%)”View highlighted excerpt for this quote“3”View highlighted excerpt for this quote“3 (4%)”View highlighted excerpt for this quote“4”View highlighted excerpt for this quote
Lower respiratory tract infection“2 (3%)”View highlighted excerpt for this quote“3”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“2 (3%)”View highlighted excerpt for this quote“3”View highlighted excerpt for this quote
Respiratory tract infection“2 (3%)”View highlighted excerpt for this quote“2”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“2 (3%)”View highlighted excerpt for this quote“2”View highlighted excerpt for this quote
Skin laceration“2 (3%)”View highlighted excerpt for this quote“2”View highlighted excerpt for this quote“1 (1%)”View highlighted excerpt for this quote“1”View highlighted excerpt for this quote“2 (3%)”View highlighted excerpt for this quote“3”View highlighted excerpt for this quote
Thermal burn“2 (3%)”View highlighted excerpt for this quote“2”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“2 (3%)”View highlighted excerpt for this quote“2”View highlighted excerpt for this quote
Headache“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“2 (3%)”View highlighted excerpt for this quote“2”View highlighted excerpt for this quote“2 (3%)”View highlighted excerpt for this quote“2”View highlighted excerpt for this quote
Study limitations
Summary

IB1001-303 randomized 73 participants at ten centers to a two-period crossover with 12 weeks of each treatment and an immediate crossover, with no washout between periods. The protocol chose an analysis that does not require a washout, and the publication describes the placebo period that followed levacetylleucine as having effectively served as a washout. The publication and the prescribing information report no result of a test for carryover or sequence effects. In the prescribing information, mean baseline fSARA was 7.3 in the sequence that started with levacetylleucine and 8.5 in the sequence that started with placebo.

The endpoint reported differs by source. The protocol names the 40-point SARA as the primary endpoint in all jurisdictions besides the United States and the 16-point functional SARA (fSARA) as a key secondary endpoint for the United States. The publication reports a SARA treatment effect of -1.88 points (95% CI -2.70 to -1.06), with mean changes of -1.92 on levacetylleucine and -0.14 on placebo. The prescribing information reports an fSARA treatment difference of -0.6 (95% CI -0.9 to -0.2; two-sided p = 0.0013) and gives no numerical SARA result. The fSARA p value is 0.001 in the publication, and the company's approval release gives a two-sided p value below 0.001.

The sample size calculation used a one-sided significance level of 5% and assumed a 1.0-point SARA difference, a threshold taken from an analysis of the sponsor's trials in lysosomal storage disorders; an independent estimate of the SARA minimal clinically important difference is 1.5 points. No adjustment for multiple comparisons was applied, and the statistical analysis plan classes every evaluation other than the primary endpoint as exploratory. The statistical analysis plan specifies descriptive summaries for the ICARS, and the publication reports a model-based ICARS treatment effect with a p value. Success of masking was not assessed. The SARA has not been validated specifically in ataxia-telangiectasia, and pediatric SARA scores are age-dependent; 47 of 73 participants (64%) were younger than 18 years.

The controlled comparison lasted 12 weeks per treatment, 55 of 73 participants (75%) were White, and eligibility required an age of 4 years or older and a SARA score of 7 to 34. Long-term efficacy and safety data depend on the open-label extension phase, which was ongoing at publication. The results were published in a peer-reviewed journal in July 2026; the trial was funded by IntraBio, and the publication acknowledges an IntraBio employee for writing and editorial assistance. The ClinicalTrials.gov record lists an estimated enrollment of 60, was last updated in July 2025, and carries no posted results. One congress abstract, submitted before data were available, states that 74 participants were randomized, and the congress results abstract states that no serious adverse events occurred, whereas the publication reports 73 randomized participants and three withdrawals associated with serious adverse events judged unrelated to treatment.

Limitations stated by the investigators

“This study has several limitations. First, the study was designed to investigate the symptomatic effects of levacetylleucine; data from the ongoing extension phase will provide further insights into its impact on ataxia-telangiectasia disease progression and continued data on the long-term safety of levacetylleucine for ataxia-telangiectasia. Second, the focus on symptomatic endpoints excluded patients younger than 4 years, asymptomatic patients, or patients with advanced disease states who would not be reliably able to complete functional assessments. Third, the study included paediatric patients; although all study assessments have been used previously in paediatric populations, not all study assessments are formally validated for use in paediatric populations. Fourth, most patients in this trial were White and of North American or European descent, and data on patients of other ethnicities were scarce or absent.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Fifth, there is no validated biomarker for ataxia-telangiectasia or a surrogate endpoint which is indicative of clinical improvement. Sixth, as with all clinical trials implementing null hypothesis significance testing, the design and sample size cannot exclude the potential of type I error. Finally, the study duration was not long enough to investigate the effects of levacetylleucine on other key features of ataxia-telangiectasia, such as immunological defects and oncological risks.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

IB1001-203

Objective
Location and study date
Registry dates and status
FieldQuoted record
Study start (actual)“2020-01-08”
Primary completion (actual)“2025-02-11”
Study completion (actual)“2025-10-27”
Results first posted“2026-03-25”
Recruitment status“Terminated”
Study design
Choice of an open-label design over a placebo-controlled crossover design
Eligibility criteria
Treatment
Study outcomes
Rationale for using clinical impression of change in severity as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Participants enrolled and analyzed
PopulationParticipants
Enrolled (actual)“17”
Analyzed for the primary endpoint“16”
Description of analysis sets
Results
Participant disposition
Participant flow by study period
Study periodStartedCompletedNot completed
Treatment with IB1001“17”“16”“1”
Post-treatment washout“16”“16”“0”
Extension phase“13”“10”“3”
Reasons for not completing
Study periodReasonParticipants
Treatment with IB1001“Adverse Event”“1”
Extension phase“Adverse Event”“1”
Extension phase“Withdrawal by Subject”“1”
Extension phase“Lost to Follow-up”“1”
Baseline characteristics
Age, sex, and ethnicity
CharacteristicValue
Participants“17”
Age, mean (standard deviation), years“23.3 (12.9)”
Female“7”
Male“10”
Hispanic or Latino“2”
Not Hispanic or Latino“15”
Efficacy results
Primary endpoint: CI-CS during treatment minus CI-CS during washout
MeasureValue
Participants analyzed“16”
Mean (standard deviation), score on a scale“0.16 (1.65)”
Components of the primary endpoint
PeriodCI-CS, mean (standard deviation)
Treatment with IB1001 (Visit 4 versus Visit 2)“0.16 (0.81)”
Post-treatment washout (Visit 6 versus Visit 4)“0.00 (1.18)”
CI-CS reclassified on a 3-point scale, number of participants
PeriodWorsened (-1)No observable change (0)Improved (+1)
Treatment with IB1001“6”“2”“8”
Post-treatment washout“7”“1”“8”
Key secondary endpoint: change in Clinical Impression of Severity
MeasureValue
Participants analyzed“16”
Mean (standard deviation), score on a scale“-0.09 (0.39)”
CI-CS for the non-primary anchor test
PeriodCI-CS, mean (standard deviation)
Treatment with IB1001“0.00 (1.07)”
Post-treatment washout“0.17 (1.03)”
Change in SARA total score
PeriodChange, mean (standard deviation)
Treatment with IB1001“-0.31 (3.47)”
Post-treatment washout“0.59 (2.99)”
Change in SCAFI total score
PeriodChange, mean (standard deviation)
Treatment with IB1001“0.0583 (0.3384)”
Post-treatment washout“0.0157 (0.1923)”
Treating physician Clinical Global Impression of Change
PeriodMeanStandard deviation
Treatment with IB1001“3.3”“0.9”
Post-treatment washout“4.8”“0.9”
Treating physician Clinical Global Impression of Severity by visit
VisitMeanStandard deviation
Visit 2 (baseline)“4.2”“1.1”
Visit 3“4.0”“1.1”
Visit 4 (end of treatment)“4.0”“1.1”
Visit 5“4.1”“1.0”
Visit 6 (end of washout)“4.1”“0.9”
Health-related quality of life and patient-reported outcomes
Caregiver and participant Clinical Global Impression of Change
RaterPeriodMeanStandard deviation
CaregiverTreatment with IB1001“3.1”“0.8”
CaregiverPost-treatment washout“4.7”“1.0”
ParticipantTreatment with IB1001“3.5”“0.9”
ParticipantPost-treatment washout“4.7”“1.1”
Caregiver and participant Clinical Global Impression of Severity by visit
RaterVisitMeanStandard deviation
CaregiverVisit 2 (baseline)“3.1”“2.0”
CaregiverVisit 4 (end of treatment)“2.9”“1.5”
CaregiverVisit 6 (end of washout)“3.4”“1.8”
ParticipantVisit 2 (baseline)“2.3”“1.6”
ParticipantVisit 4 (end of treatment)“2.4”“1.8”
ParticipantVisit 6 (end of washout)“2.9”“1.8”
Safety results
Deaths, serious adverse events, and other adverse events by period
CategoryTreatment with IB1001Post-treatment washoutExtension phase
All-cause mortality“0/17 (0.00%)”“0/17 (0.00%)”“1/13 (7.69%)”
Serious adverse events“1/17 (5.88%)”“0/17 (0.00%)”“2/13 (15.38%)”
Other (not including serious) adverse events“9/17 (52.94%)”“2/17 (11.76%)”“11/13 (84.62%)”
Non-serious adverse events reported during the parent study
EventTreatment with IB1001Post-treatment washout
Abdominal pain upper“2/17 (11.76%)”“1/17 (5.88%)”
Nasopharyngitis“1/17 (5.88%)”“0/17 (0.00%)”
Oral herpes“1/17 (5.88%)”“0/17 (0.00%)”
Respiratory tract infection“1/17 (5.88%)”“0/17 (0.00%)”
Upper respiratory tract infection“1/17 (5.88%)”“0/17 (0.00%)”
Chorea“1/17 (5.88%)”“0/17 (0.00%)”
Syncope“1/17 (5.88%)”“0/17 (0.00%)”
Fatigue“1/17 (5.88%)”“0/17 (0.00%)”
Hypertransaminasaemia“1/17 (5.88%)”“0/17 (0.00%)”
Pollakiuria“1/17 (5.88%)”“0/17 (0.00%)”
Menstruation irregular“1/17 (5.88%)”“0/17 (0.00%)”
Cough“1/17 (5.88%)”“0/17 (0.00%)”
Hyperhydrosis“1/17 (5.88%)”“0/17 (0.00%)”
Gastrointestinal lymphoma“1/17 (5.88%)”“0/17 (0.00%)”
Diarrhoea“0/17 (0.00%)”“1/17 (5.88%)”
Muscle spasms“0/17 (0.00%)”“1/17 (5.88%)”
Non-serious adverse events reported during the extension phase
EventExtension phase
Diarrhoea“3/13 (23.08%)”
Nasopharyngitis“2/13 (15.38%)”
Respiratory tract infection“1/13 (7.69%)”
Bronchitis“1/13 (7.69%)”
Candida infection“1/13 (7.69%)”
Corona virus infection“1/13 (7.69%)”
Dysphagia“1/13 (7.69%)”
Vomiting“1/13 (7.69%)”
Gait disturbance“1/13 (7.69%)”
Fall“1/13 (7.69%)”
Hand fracture“1/13 (7.69%)”
B-lymphocyte count abnormal“1/13 (7.69%)”
T-lymphocyte count abnormal“1/13 (7.69%)”
Type 2 diabetes mellitus“1/13 (7.69%)”
Muscle spasms“1/13 (7.69%)”
Myalgia“1/13 (7.69%)”
Speech disorder“1/13 (7.69%)”
Tremor“1/13 (7.69%)”
Micturition urgency“1/13 (7.69%)”
Study limitations
Summary

IB1001-203 was a single-group, open-label trial in which each participant's 6-week post-treatment washout served as the comparison for the 6-week treatment period. Blinded raters scored the primary endpoint from video recordings; the SARA, the SCAFI, and the clinical global impression scales were recorded at the study sites under open-label conditions. The protocol planned approximately 39 enrolled participants and calculated 76% power with 30 participants. The sponsor terminated the trial after 17 participants were enrolled, and 16 were analyzed. The registry posts a mean and standard deviation for each endpoint and no statistical test. The posted primary endpoint was a mean of 0.16 (standard deviation 1.65), and on the 3-point reclassification 8 of 16 participants were rated improved after treatment and 8 of 16 after washout. The extension phase was unblinded. Its primary endpoint was the CI-CS in the 2021 master protocol and the SARA in protocol version 7.0. Extension phase efficacy results are available from a conference abstract covering 12 participants at 1 year and 7 participants at 2 years, and the abstract does not describe the natural history cohort used for its comparison of progression rates.

Mashhad N-acetyl-L-leucine crossover trial

Objective
Location and study date
Registry record
FieldQuoted record
Registration number“IRCT20210413050958N1”
Registration date“2021-10-27, 1400/08/05”
Registration timing“prospective”
Recruitment status“Recruitment complete”
Expected recruitment start date“2021-12-06, 1400/09/15”
Expected recruitment end date“2022-08-06, 1401/05/15”
Recruitment center“Ghaem Hospital”
City“Mashhad”
Sponsor and funding source“Mashhad University of Medical Sciences”
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using SARA and SCAFI scores as the primary endpoints
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Availability of the statistical analysis plan
Results
Participant disposition
Baseline characteristics
Efficacy results
Health-related quality of life and patient-reported outcomes
Safety results
Study limitations
Summary

The trial randomized 16 participants at one hospital after 4 of 20 were excluded, with 6-week treatment periods separated by a 4-week washout. The participants had a mean age of 9.8 years. The abstract reports the comparisons with placebo as p > 0.05 and gives no effect estimates, confidence intervals, or scores by period. The registry names Hubei ipure Biotech as the source of the N-acetyl-L-leucine caplets, dosed at 1 to 4 g per day by weight, and states that no statistical analysis plan will be shared. A 2026 systematic review rated the trial as having “some concerns” on the RoB 2 tool and listed limited duration and a potential carry-over effect as its limitations. The evidence quoted here comes from the article's abstract and the registry record.

Acetyl-DL-leucine case series

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using SARA total score as an efficacy outcome
Statistical analysis description
Number of participants (Planned and analyzed)
Participants treated and assessed
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Efficacy results
Health-related quality of life and patient-reported outcomes
Safety results
Study limitations
Summary

The series included six participants treated open label with the racemate acetyl-DL-leucine and had no control group. Follow-up measurements were made at 1 month in 5 participants and at 6 and 12 months in 1 participant. The abstract reports no adverse event or quality-of-life results. A 2026 systematic review rated the quality of the study as low on the National Institutes of Health tool for studies without a control group and listed limited duration and incomplete assessment in some cases as its limitations. The evidence quoted here comes from the article's abstract.

Acetyl-DL-leucine case report

Objective
Location and study date
Study design
Eligibility criteria

Not applicable.

Treatment
Study outcomes
Rationale for using SARA score as an efficacy outcome
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets

Not applicable.

Results
Participant disposition

No evidence found.

Baseline characteristics
Efficacy results
Health-related quality of life and patient-reported outcomes
Safety results
Study limitations
Summary

The report describes one participant, a 9-year-old girl, treated with the racemate N-acetyl-DL-leucine at 4 g per day for 16 weeks without a comparator. The abstract gives the change in SARA score (11.0 points, 48.88%) without the baseline score and does not describe blinding of the assessor. Nausea and constipation occurred in the first week. The evidence quoted here comes from the article's abstract.